Outcome of iatrogenic choroidal neovascularisation in sickle cell disease

Peter D Fox, Robert W Acheson, Graham R Serjeant

Abstract
Choroidal neovascularisation developed in 62/66 (94%) eyes followed up for a mean period of 11-2 years after treatment with xenon arc feeder vessel coagulation for proliferative sickle retinopathy (PSR). In 27 eyes the neovascularisation was chorioretinal alone and in 35 eyes chorioretinal. Chorioretinal neovascularisation (CRN) was a benign complication but may convert to chorioretinal neovascularisation (CVN). Late sequelae of CVN included vitreous haemorrhage, posterior vitreous face fibrosis, and tractional retinal detachment. Visual loss (of ≥ 3 Snellen lines for ≥ 3 months) occurred in nine eyes affected by choroidal neovascularisation, though because of other pathology this could not always be attributed to the choroidal neovascularisation. The incidence of visual loss in CVN affected eyes was significantly greater, by survival curve analysis, than in eyes affected by CRN alone. Permanent visual loss from tractional retinal detachment definitely attributable to CVN occurred in 2/35 (6%) eyes.

Treatment of proliferative sickle retinopathy (PSR) by feeder vessel coagulation achieves closure of the new vessels in most patients.1 Choroidal neovascularisation at the coagulation site is a serious complication of feeder vessel treatment because of the risk of subsequent vitreous haemorrhage or retinal traction.4,5 However, the long term risk to visual function is unknown, and the experience with iatrogenic choroidal neovascularisation in 62 affected eyes monitored for a mean period of 11-2 years is therefore reported.

Patients and methods
Patients treated were in two consecutive trials of xenon arc feeder vessel coagulation of proliferative sickle retinopathy at the Sickle Cell Clinic, University of the West Indies, and were invited to attend for further review. They were enrolled between March 1973 and January 1977 in a non-randomised trial1 which assessed coagulation of both the feeding arteriole and the new vessels, and in a controlled randomised trial2 between April 1978 and September 1980 of coagulation of the feeding arteriole only. Of the 103 treated patients 29 were known to have emigrated, four had died, and 13 could not be traced. In the remaining 57 patients who attended for review there were 66 treated eyes of which 31 were treated in the first trial and 35 in the second. There were 40 patients with sickle cell-haemoglobin C (SC) disease, 12 with homozygous sickle cell (SS) disease, three with sickle cell-beta' thalassaemia, and two with sickle cell-beta thalassaemia.

The most recent assessment in 1988 included ocular symptoms, corrected acuities, fundal examination, and fluorescein angiography. The previous notes and angiograms were reviewed to determine the type, onset, and behaviour of any choroidal neovascularisation. These abnormal vessels may remain in the plane of the choroidal scarring (CRN) or may extend into the vitreous (CVN). The mean follow-up of all 66 eyes from initial treatment until review in 1988 or until an eye had no perception of light was 11-2 years (range 7-5 to 15-4 years, except for one eye which had reached no perception of light after 3-2 years' follow-up). Visual loss was defined as a decrease in acuity of 3 or more Snellen lines for three or more months (using Snellen lines 6/6, 6/9, 6/12, 6/18, 6/24, 6/36, 6/60).

Results
Choroidal neovascularisation developed in 62/66 treated eye (94%). CRN alone developed in 27 eyes and both CVN and CRN in 35 eyes. A total of 173 CRN lesions were identified in 62 eyes (range 1-6 per eye) and 70 CVN lesions in 35 eyes (range 1-4 per eye, involving 10–120° circumferentially).

Age, sex, genotype, and trial protocol did not influence the type of choroidal neovascularisation that developed, and no features distinguished the four eyes that did not develop choroidal neovascularisation. The mean age of all patients at initial treatment was 33-8 years (range 13-2–67-1 years).

Nine patients received bilateral treatment, of whom eight developed choroidal neovascularisation (unilateral CVN in one, bilateral CRN in two, bilateral CVN in two, and CRN in one eye and CVN in the other in three patients).

Ophthalmoscopic and angiographic appearances
On ophthalmoscopy CRN appeared as a dirty white membrane within a coagulation scar and was usually surrounded by hyperpigmentation. CVN was whiter, more fibrous, and extended up to the vitreous, often overlying anterior untreated retina.

On fluorescein angiography of CRN a fine vessel system could often be identified in early phases of the study (Fig 1A), but the characteristic finding was of hyperfluorescence confined to the coagulation scar in later phases of the study (Fig 1B). CVN usually showed a typical arborescent pattern in early phases of the angiogram (Fig 2A) which leaked profusely in later phases.
of the study (Fig 2B). The CVN feeding vessels usually passed through an area of CRN.

ONSET AND FOLLOW-UP OF CHOROIDAL NEOVASCULARISATION

The mean time interval between treatment and diagnosis was 1-3 years for CRN (in all 62 eyes developing choroidal neovascularisation) and 3-8 years for CVN. Chorioretinal neovascularisation was observed within one year of treatment in 37/62 eyes (60%) and within 35 days in one eye. Choriovitreal neovascularisation developed in 6/35 eyes (17%) in the first year and was first observed at 60 days in one eye. Most CVN developed between one and three years after treatment, though the observed interval was up to 7-8 years. The mean follow-up from the diagnosis of choroidal neovascularisation to last assessment was 9-9 years for CRN and 7-4 years for CVN.

GROWTH AND REGRESSION

Of the 173 CRN lesions identified in 62 eyes 25 (in 16 eyes) were CRN/CVN complexes when first observed. During follow-up a further 41 CRN lesions (in 25 eyes) converted into CRN/CVN complexes, of which one followed xenon arc photocoagulation of a CRN lesion. Only four CVN lesions (in four eyes) did not have identifiable associated CRN. Of the 70 CVN lesions (in 35 eyes) angiograms adequate to assess behaviour were available for 57 lesions (in 30 eyes), of which 15 (in 10 eyes) enlarged 11 (in 9 eyes) regressed, nine (in 6 eyes) initially grew and later regressed, and 18 (in 13 eyes) remained stable on follow-up. There was no difference in length of follow-up of lesions manifesting growth, regression or stability. Xenon arc photocoagulation of the remaining four CVN lesions in three eyes (misdiagnosed as PSR) resulted in non-perfusion of all four, but subsequently three became reperfused and one remained non-perfused 7·2 years later. Growth of CVN lesions (Figs 3A, B) usually occurred in the two years following diagnosis, though it did occur between 5·8 and 6·3 years later in one lesion. Of the 20 CVN lesions showing spontaneous regression, this proceeded to non-perfusion in seven CVN lesions over intervals of 1·6-5·7 years from diagnosis, and haemorrhage into the CVN preceded regression in four lesions.

VITREOUS HAEMORRHAGE

Vitreous haemorrhage occurred in 19 eyes and
Outcome of iatrogenic choroidal neovascularisation in sickle cell disease

Figure 3: Superior region of right eye in a 43-year-old male with SC disease with chorioroidal neovascularisation 3-4 years after treatment. (A) One year after diagnosis of CVN. (B) One year later showing spontaneous growth.

Table 1: Visual loss in eyes with choroidal neovascularisation

<table>
<thead>
<tr>
<th>Case</th>
<th>Age at treatment (years)</th>
<th>Sex and visual loss genotype</th>
<th>Treatment to Visual acuity</th>
<th>Initial</th>
<th>Worst</th>
<th>Final</th>
<th>Cause of visual loss</th>
<th>Type of new vessels</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>48</td>
<td>M SS 6-7</td>
<td>6/6 2/60 2/60</td>
<td>Epiretinal membrane</td>
<td>CRN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>51</td>
<td>M SC 9-6</td>
<td>6/6 6/36 6/36</td>
<td>Epiretinal membrane</td>
<td>CVN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>28</td>
<td>F SC 12-0</td>
<td>6/6 6/60 6/60</td>
<td>Epiretinal membrane</td>
<td>CVN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>32</td>
<td>M SC 11-9</td>
<td>6/6 HM 6/12</td>
<td>Vitreous haemorrhage</td>
<td>CVN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>57</td>
<td>F SS 1-6</td>
<td>6/12 6/60 6/12</td>
<td>Vitreous haemorrhage</td>
<td>CVN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>38</td>
<td>F SC 9-4</td>
<td>6/6 6/60</td>
<td>Vitreous haemorrhage</td>
<td>CVN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>37</td>
<td>M SS 7-7</td>
<td>6/6 6/60 6/60</td>
<td>Trabecular detachment</td>
<td>CVN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>22</td>
<td>M SC 3-2</td>
<td>6/6 NPL 6/60</td>
<td>Vitreous haemorrhage</td>
<td>CVN and PSR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>44</td>
<td>F SC 9-2</td>
<td>6/6 NPL 6/60</td>
<td>Trabecular detachment</td>
<td>CVN and PSR</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HM = hand movement. NPL = no perception of light.

Discussion

Choroidal neovascularisation was a common complication of feeder vessel coagulation of proliferative sickle retinopathy, and although occurring more frequently with xenon arc, occurs also with argon laser photocoagulation. Choroidal neovascularisation has not only been induced by small, intense photocoagulation burns in rhesus monkeys, and histological examination confirmed vasoproliferation through defects in Bruch’s membrane. Retinal ischaemia, choroidal ischaemia, and post-photocoagulation inflammation have all been postulated as stimuli for choroidal neovascularisation in sickle cell retinopathy following disruption of Bruch’s membrane by photocoagulation. Since the frequency of choroidal neovascularisation did not differ between the two therapeutic protocols employed in the Jamaican studies, it seems unlikely that the more extensive photocoagulation in the first trial was a causal factor.

The development of choroidal neovascularisation in the great majority of patients receiving feeder vessel coagulation for PSR has raised the...
concern that one neovascular network has been replaced by another which may have an equally bad or possibly worse visual prognosis. Complications from choroidal neovascularisation in sickle cell disease include vitreous haemorrhage, vitreoretinal traction, and tractional retinal detachments, but the long term risk to visual function remained to be determined. Earlier reports describing short term follow-up were contradictory. In 16 eyes developing CVN, followed up at this unit for a mean period of 3·3 years, increasing retinal traction was observed in one eye, but there was no visual loss. In Chicago, 10 eyes developed CVN following argon laser feeder vessel coagulation of PSR, and during a mean follow-up of 4·2 years three developed tractional retinal detachments, two of which involved the macula. However, the same group later described nine eyes with CVN over a mean follow-up of 5·8 years and found no permanent profound visual loss.

Longer term follow-up in the present study indicates that CRN was a benign complication, though conversion to CVN occurred in 41 lesions occasionally several years later. Vitreous haemorrhage from a CVN was common and often recurrent, but visual loss was unusual. Posterior vitreous face fibrosis attached to CVN was a more ominous sign, and progression to tractional retinal detachment and irretrievable visual loss were observed. Visual loss from macular epiretinal membranes was difficult to attribute to CRN or CVN because the complication may follow photocoagulation, vitreous haemorrhage, and PSR itself. The risk of visual loss in the present study was significantly greater in eyes developing CVN than CRN, and the incidence rate of visual loss in CVN eyes was similar to that observed in untreated eyes with PSR in this unit.

This observation indicates that little has been achieved by the treatment of PSR if choriovitreal neovascularisation develops as a complication. Although it is commoner after xenon arc therapy, this complication also occurs with argon laser photocoagulation, and protocols for treatment by both methods should be changed so as to minimise the risks of development of choroidal neovascularisation.

Outcome of iatrogenic choroidal neovascularisation in sickle cell disease.

P D Fox, R W Acheson and G R Serjeant

doi: 10.1136/bjo.74.7.417

Updated information and services can be found at:
http://bjo.bmj.com/content/74/7/417

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/